Company

Kaleido Biosciences, Inc.

Headquarters: Lexington, MA, United States

Employees: 82

CEO: Mr. Daniel L. Menichella B.A., M.B.A.

NASDAQ: KLDO

Market Cap

$106,556

USD as of Jan. 1, 2023

Market Cap History

Kaleido Biosciences, Inc. market capitalization over time

Evolution of Kaleido Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Kaleido Biosciences, Inc.

Detailed Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It also has a strategic collaboration with the COPD Foundation to study KB109 in patients with chronic obstructive pulmonary disease. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Kaleido Biosciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: KLDO wb_incandescent

Details

Headquarters:

65 Hayden Avenue

Lexington, MA 02421

United States

Phone: 617 674 9000